SUPN
Supernus Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +1.6% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | +2 | 42.40M | $1.97B | +5 | −5 |
| Q1 2026 | 104 | -3 | 41.20M | $2.13B | +5 | −9 |
| Q4 2025 | 107 | 0 | 43.16M | $2.15B | +1 | n/a |
| Q3 2025 | 18 | -1 | 27.64M | $1.32B | n/a | −2 |
| Q2 2025 | 17 | 0 | 22.78M | $717.88M | n/a | n/a |
| Q1 2025 | 14 | 0 | 6.75M | $221.22M | n/a | n/a |
| Q4 2024 | 14 | 0 | 6.49M | $234.56M | +1 | −1 |
| Q3 2024 | 13 | 0 | 4.54M | $141.67M | +1 | −1 |
| Q2 2024 | 13 | n/a | 4.27M | $114.18M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 9.37M | n/a | $295.28M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 2 | The Vanguard Group ✦ (passive) | 6.21M | n/a | $195.59M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 2.21M | +3.0% | $69.61M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 4 | Renaissance Technologies ✦ | 1.66M | +4.4% | $52.18M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.40M | +5.5% | $44.12M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 598.62K | +27.9% | $18.87M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Point72 Asset Management ✦ | 507.79K | +59.2% | $16.01M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 247.98K | -3.3% | $7.82M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 175.13K | +8.4% | $5.52M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 10 | AQR Capital Management ✦ | 140.56K | +64.9% | $4.43M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 11 | Fidelity (FMR) ✦ | 80.85K | n/a | $2.55M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 57.30K | -41.1% | $1.81M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 47.30K | +11.2% | $1.49M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 14 | Norges Bank ✦ (passive) | 31.41K | -55.7% | $989,886 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Wellington Management ✦ | 20.99K | -5.5% | $661,700 | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
| 16 | Gotham Asset Management ✦ | 17.62K | -42.6% | $555,477 | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 17 | Millennium Management ✦ | 13.07K | -90.9% | $412,061 | 0.0% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 323 holders, 57.94M shares, $2.88B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.